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Abstract: Preclinical drug development for human chronic lymphocytic leukemia (CLL) requires
robust xenograft models recapitulating the entire spectrum of the disease, including all prognostic
subgroups. Current CLL xenograft models are hampered by inefficient engraftment of good prognostic
CLLs, overgrowth with co-transplanted T cells, and the need for allogeneic humanization or irradiation.
Therefore, we aimed to establish an effective and reproducible xenograft protocol which allows
engraftment of all CLL subtypes without the need of humanization or irradiation. Unmanipulated
NOD.Cg-PrkdcscidIl2rgtm1Sug/ JicTac (NOG) mice in contrast to C.Cg-Rag2tm1Fwa-/-Il2rgtm1Sug/ JicTac
(BRG) mice allowed engraftment of all tested CLL subgroups with 100% success rate, if CLL cells
were fresh, injected simultaneously intra-peritoneally and intravenously, and co-transferred with
low fractions of autologous T cells (2%–4%). CLL transplanted NOG mice (24 different patients)
developed CLL pseudofollicles in the spleen, which increased over 4–6 weeks, and were then limited
by the expanding autologous T cells. Ibrutinib treatment studies were performed to validate our
model, and recapitulated treatment responses seen in patients. In conclusion, we developed an
easy-to-use CLL xenograft protocol which allows reliable engraftment for all CLL subgroups without
humanization or irradiation of mice. This protocol can be widely used to study CLL biology and to
explore novel drug candidates.
Keywords: CLL; xenograft; microenvironment
1. Introduction
Chronic lymphocytic leukemia (CLL) is characterized by a progressive accumulation of functionally
incompetent CD5+ B-lymphocytes in the peripheral blood (PB), bone marrow (BM), and lymphoid
organs [1,2]. CLL cells can account for up to 99% of circulating peripheral blood mononuclear cells
(PBMCs), and thereby decrease the number of normal hematopoietic cells [3,4]. The disease has a
highly variable clinical course. Some patients die from the disease within a few months, whereas
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others live for 20 years or more even without treatment [5]. Several prognostic markers such as Rai
and Binet staging systems, immunoglobulin VH gene mutational status [6], ζ-associated protein 70
(ZAP70) expression [7,8], cytogenetic abnormalities [9], and gene mutations can be used to predict the
survival outcome and the need for treatment of patients with CLL [10,11]. While del 17p or del 11q
CLL samples are highly aggressive and resistant to many chemotherapeutic agents, del 13q14 or a
normal karyotype are associated with a good prognosis. In vitro monocultures of CLL cells are limited,
and can only be used for drug screens based on short term readouts [12]. Co-culture of CLL cells with
nurse-like cells or BM-stroma derived cell lines can maintain CLL survival for several days [13,14],
but none of the available in vitro culture systems allow long-term culture or proliferation of CLL cells,
which limits the relevance of such models for testing novel drugs [15].
Transgenic mouse models which show key features of human CLL have been developed by
several groups to study the disease. The Eµ-TCL1 tg mouse model recapitulates many features of an
aggressive CLL with increasing numbers of CD5+ CD19+ lymphocytes expanding in spleen, PB and
BM leading to death of the mice within 1–1.5 years [16]. The double transgenic BCL-2:Traf2DN mouse
model mimics refractory CLL and mice develop increased B cell counts with severe splenomegaly and
lymphadenopathy by 6 months of age [17]. The cluster-deleted DLEU2/miR15a/16-1 replicates the
deletion of the chromosomal region 13q14 and mice develop a more indolent CLL phenotype [18].
However, these transgenic mouse models do not yet cover the entire spectrum of human CLL subtypes.
Notably, CLL characterized by major chromosomal changes like trisomy 12, del 17p or del 11q have
not yet been amenable to transgenic methods based on single-gene modifications.
There are also notable limitations in the use of xenograft models which either use established
human CLL cell lines [19,20], or mainly late stage and poor-prognosis primary CLL samples [21]. Thus,
in 1997 the first CLL xenograft mouse model was developed [22]. CLL cells were injected into the
peritoneal cavity of lethally irradiated Balb/c mice reconstituted with BM of SCID mice (lack of B and T
cells), allowing short-term engraftment of late-stage CLL samples within the peritoneum for up to
2 weeks. Early stage CLL samples (RAI 0-I) only showed T cell engraftment, but their short-term
engraftment could be improved by in vivo depletion of co-injected T cells with an OKT3 antibody [23].
The protocol was significantly improved by Dürig et al. using sublethally irradiated nonobese diabetes
(NOD)/SCID mice as recipients which have additionally low NK cell activity and lack circulating
complement. These researchers combined intra-peritoneal (i.p.) and intra-venous (i.v.) injections of
PBMCs from CLL patients, and achieved a highly reproducible splenic and peritoneal engraftment
with mainly late stage and poor prognostic CLL samples that remained stable for 4–8 weeks [24].
Other groups, using chemotherapy-based conditioning regimens with busulfan, have achieved similar
results [21,25,26]. Systematic analysis of prognostic factors demonstrated favorable engraftment for
CLL samples with poor prognosis including unmutated IGVH genes, CD38 expression and ZAP70
expression [26]. Further progress was made by the use of humanized mice. The Chiorazzi group
used an allograft setting and humanized irradiated NSG mice with human cord blood-derived CD34+
cells, human mesenchymal stromal cells, as well as mature human antigen-presenting CD14+ and
CD19+ cells followed by injection of CLL-PBMCs, allowing CLL engraftment over several weeks. They
found a clear correlation between numbers of proliferating autologous T cells with proliferation and
frequency of engrafting CLL cells. In contrast to the previously published papers they showed that T
cell proliferation is essentially required for CLL cell proliferation and that depletion of T cells completely
blocked CLL engraftment in vivo [27]. Therefore, they further refined this protocol by activating CD3+
cells from CLL patients for 3–14 days with CD3/CD28 Dynabeads and IL-2 and transferred them
with CLL-PBMCs into NSG mice via the retro-orbital vein [28–30]. Although they could engraft even
good prognostic CLLs [27], major drawbacks of these models are the use of conditioning regimens,
such as chemotherapy or irradiation, which irreversibly alter the microenvironment and the leukemic
niche, and their reliance on allogeneic settings triggering immunological processes with unforeseeable
implications on CLL biology.
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Therefore, the aim of the presented study was to establish an easy-to-use, effective, and reliable
protocol to generate CLL xenograft mouse models with both poor and good prognosis CLLs,
avoiding irradiation, chemotherapeutic conditioning regimens, or allogeneic settings. Specifically,
we compared the CLL engraftment capacity of C.Cg-Rag2tm1Fwa-/-Il2rgtm1Sug/ JicTac (BRG) versus
NOD.Cg-PrkdcscidIl2rgtm1Sug/ JicTac (NOG) mice in the absence of any conditioning regimen, as these
mouse strains are the backbone for most future developments. Furthermore, we aimed to determine the
role of fresh versus frozen samples, frequencies of co-transplanted T cells, and to validate the resulting
optimized protocol with regard to treatment responses to the BTK inhibitor ibrutinib. Taken together,
we established an easy-to-use protocol for xenografting all CLL subtypes which can be broadly used to
validate novel treatment strategies and to study CLL biology in vivo.
2. Results
2.1. Reliable CLL Engraftment is Detectable in NOG, but Not BRG Mice
Previous publications have shown huge advantages in CLL cell engraftment for late stage CLLs
(Rai stage III/IV) [23,24,31] and CLL subsets with poor prognosis [21], but at least half of the patients
seen in the clinic present with genetic and expression features of good prognosis and early stage CLL.
Furthermore, many xenograft models rely on complicated conditioning regimens (chemotherapy,
irradiation) or allogeneic settings. The aim of our study was therefore to establish an easy-to-use
xenograft protocol for the good prognosis and early stage CLL subgroup, without any further
interventions. NOG mice [32] and BRG mice [33] are currently the most immunocompromised basic
mouse strains available, and are the backbone for the development of many new mouse models like
humanized mice. CLL samples from 24 different patients were injected i.v. and i.p. into NOG and BRG
mice and their engraftment capacity in the two different unconditioned mouse strains was compared.
Figure 1A shows the engraftment of seven patients with good/intermediate prognosis and Rai
0-II into NOG versus BRG mice (Patient information Table S1, Data analysis Table S2). For each
CLL sample tested, a total of 70 x 106 freshly isolated CLL-PBMCs were injected into 9–11 weeks old
recipients (n = 4/strain and Patient). As previously shown from the Dürig group, we observed the
highest transplantation efficiency with combined i.v./i.p. injections of CLL PBMCs [24]. Four weeks
after transplantation we could detect reproducible and stable engraftment (flow cytometry) of all
the different CLL patient samples in NOG mice (Table S2). Human cell engraftment detected by
human CD45+ cells was highest in the spleen, followed by blood and BM. NOG mice demonstrated an
enormous engraftment advantage over BRG mice in all analyzed patient samples (Table S2, 4 mice per
patient and mouse strain).
Human cell recovery in NOG versus BRG mice 4 weeks after injection was 41.4% (NOG) versus
7.2% (BRG), huCD45+ cells in the spleen 29.8% (NOG) vs. 1.5% (BRG), and 8.8% vs. 0.2% in the
BM. Total and relative numbers of CLL cells were significantly and markedly (>10-fold) higher in
NOG mice compared to BRG mice, as shown in the spleen (35.604 vs. 1.167 CLL cells), femur (1.787
vs. 577 CLL cells), and blood (1.861 vs. 135 CLL cells) (Figure 1A, B; single data analysis Table
S2). Human cell populations were separated by using human CD45, CD5 and CD19 staining. CLL
cells were CD5+CD19+CD45+, B cells CD5-CD19+CD45+ and T cells CD5+CD19-CD45+. Figure 1C
demonstrates the gating strategy and shows a representative example for the engraftment of human
CLL-, B- and T cells in NOG (left) versus BRG (right) mice, demonstrating the enormous differences in
engraftment ability in the two different unmanipulated mouse strains.
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numbers (huT) in the spleen, femur and PB of CLL-PBMC transplanted NOG and BRG mice 28 days 
after human cell injection (CLL patients #1–#7, n = 4 per mouse strain, total of 26–28 mice per mouse 
strain). (B) Mean relative numbers of human CLL-, B- and T cells engrafting in the spleen, BM and PB 
of NOG and BRG mice 28 days after transplantation (CLL patients #1–#7, n = 4 per mouse strain, total 
of 26–28 mice per mouse strain). (C) Representative example for flow cytometry analysis for huCD45, 
CD5 and CD19 of the spleens of NOG versus BRG mice four weeks after human cell injection (CLL 
patient #1). Human cell engraftment was analyzed by gating on human CD45+ cells, and the 
distribution of human CLL- (CD5+CD19+), B- (CD5-CD19+) and T cells (CD5+CD19-) by additional 
gating on CD5 and CD19. 
2.2. Human CLL Cells and T Cells Expand during the First Weeks of Engraftment in NOG Mice, but Not in 
BRG Mice 
To follow the course of human cell engraftment and human cell expansion over time, PB 
samples of CLL-PBMC transplanted NOG and BRG mice (4 mice per patient and mouse strain) as 
well as age-matched non-transplanted control mice (n = 3 per mouse strain) were collected two, four, 
and eight weeks after transplantation. In BRG mice, no increase in circulating human CLL cells, B 
cells or T cells was observed from day 14 to day 28.  
By contrast, there was a strong and significant increase in all circulating human cell types in the 
initial period after transplantation in NOG mice (day 14 to 28), indicating stable engraftment and 
even expansion of the human lymphoid cell compartments in this mouse strain. For instance, CLL 
cell numbers in the PB of NOG mice increased about 3-fold within 14 days (day 14 to 28) (Figure 2A). 
Figure 1. Engraftment comparison of chronic lymphocytic leukemia (CLL-), B- and T cells in spleen,
bone marrow (BM) and peripheral blood (PB) of NOD.Cg-PrkdcscidIl2rgtm1Sug/ JicTac (NOG) versus
C.Cg-Rag2tm1Fwa-/-Il2rgtm1Sug/ JicTac (BRG) mice. (A) Mean total human CLL-, B- (huB) and T cell
numbers (huT) in the spleen, femur and PB of CLL-PBMC transplanted NOG and BRG mice 28 days
after human cell injection (CLL patients #1–#7, n = 4 per mouse strain, total of 26–28 mice per mouse
strain). (B) Mean relative numbers of human CLL-, B- and T cells engrafting in the spleen, BM and
PB of NOG and BRG mice 28 days after transplantation (CLL patients #1–#7, n = 4 per mouse strain,
total of 26–28 mice per mouse strain). (C) Representative example for flow cytometry analysis for
huCD45, CD5 and CD19 of the spleens of NOG versus BRG mice four weeks after human cell injection
(CLL patient #1). Human cell engraftment was analyzed by gating on human CD45+ cells, and the
distribution of human CLL- (CD5+CD19+), B- (CD5-CD19+) and T cells (CD5+CD19-) by additional
gating on CD5 and CD19.
2.2. Human CLL Cells and T Cells Expand during the First Weeks of Engraftment in NOG Mice, but Not in
BRG Mice
To follow the course of human cell engraftment and human cell expansion over time, PB samples
of CLL-PBMC transplanted NOG and BRG mice (4 mice per patient and mouse strain) as well as
age-matched non-transplanted control mice (n = 3 per mouse strain) were collected two, four, and
eight weeks after transplantation. In BRG mice, no increase in circulating human CLL cells, B cells or T
cells was observed from day 14 to day 28.
By contrast, there was a strong and significant increase in all circulating human cell types in the
initial period after transplantation in NOG ic ( t ), i icating stable engraftment and
even xpansion of the human lymphoid cel co p is ouse strain. For instance, CLL
cell numbers in the PB of NOG mice increased ithin 14 days (day 14 to 28) (Figure 2A).
The expansion of human lymphoid cells in NOG mice was accompanied by progressive leukocytosis,
anemia with reduced red blood cell (RBC), hemoglobin (HGB) and hematocrit (HCT) values, and
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pronounced thrombocytopenia at 28 days post-transplantation (Figure 2B). There was a positive
correlation between engraftment of CLL cells in BM and PB, while spleen engraftment was completely
independent (Figure 2C).
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Figure 2. Human CLL cells and T cells expand during the first weeks of engraftment in NOG mice
but not in BRG mice. (A) Mean human cell expansion in the PB of CLL-PBMC transplanted NOG
(n = 26–28; 7 patients in 4 mice each) and BRG (n = 28; 7 patients in 4 mice each) mice two and four
weeks after human cell injection (CLL patients #1–#7). CLL cells were characterized as human CD45+,
CD19+ and CD5+; human B cells were detected as CD45+, CD5- and CD19+; human T cells were
detected as huCD45+, CD19- and CD5+. (B) Mean white blood cell counts (WBC), red blood cell counts
(RBC), and platelet (PLT) counts, hemoglobin and hematocrit of non-transplanted age-matched control
mice, CLL-PBMC transplanted NOG (n = 26–28; 4 p r 7 patie ts) and BRG mice (n = 28; 4 per 7 patients),
analyzed at days 0, 14 and 28 aft r transplantation (CLL pa ie ts #1–#7). (C) Correlation of CLL cell
engraftment in the blood with CLL cell engraftmen in the sp een (left) or BM (right) of transplanted
NOG mice our weeks after transplantation (CLL p ti nts #1–#7) using Pearson correlation calc lation.
At 8 weeks after transplantation, the number of CLL- and B- cells slowly decreased, but was still
well detectabl . Numbe s of human T cells stay d at equal levels between d28 and d56 (Figure S1).
2.3. CLL Cells Rebuild Lymphoid Follicles in the Spleen of NOG Mice, but Not BRG Mice
Next, we compared the engraftment patterns of human CLL cells in spleen and liver tissues of
NOG and BRG recipient mice. At 28 days post-tra splantation, we observed incre sed spleen and liver
weights in the CLL-PBMC transplanted mice c mpared to age-matched, non-tra spl nted control mice
(Figure 3A). While BRG mice showed only minor, non-significant spleen weight increases, the spleen
weights in NOG mice more than doubled (mean values: 0.025 g compared to 0.089 g) as a result of
CLL transplantation (Figure 3A). Next, spleen and liver sections were stained with NACE, to identify
remaining murine granulocytes, and for human CD45, CD20 and CD7, to identify transplanted CLL
and T cells. In the non-transplanted control setting, both NOG and BRG mice are characterized by
small spleen sizes and lack of lymphoid follicles, with predominance of erythroid cells, granulocyte
lineage cells and megakaryocytes (Figure 3B). By contrast, NOG mice at 28 days after injection of
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CLL cells show numerous nodular structures of lymphoid infiltrates displacing the erythroid and
granulocytic compartments in the spleen (Figure 3B).
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Figure 3. CLL cells rebuild lymphoid follicles in the spleen of NOG mice but not in BRG mice.(A) Mean
spleen and liver weights of CLL-PBMC (peripheral blood mononuclear cells) transplanted NOG (n = 26,
CLL Patients #1–#7)) and BRG (n = 28, CLL Patients #1–#7)) mice, and age-matched non-transplanted
control mice at day 28 post transplantation. (B) NACE staining of spleen sections of transplanted
NOG and BRG mice four weeks after human cell injection (CLL Patient #1). Image size: ×25 original
magnification for upper images (bar indicates 500 µm) and×400 original magnification for lower images
(bar indicates 50µm). (C) Immunohistochemistry (IHC) analysis of spleen samples from CLL-PBMC
transplanted NOG and BRG mice stained for human CD20, at day 28 after human cell injection (CLL
Patient #1). Image size: ×25 original magnification for upper images (bar indicates 500 µm) and ×400
original magnification for lower images (bar indicates 50 µm). (D) IHC analysis of spleen samples from
CLL-PBMC transplanted NOG mice stained for human CD20, at four weeks after human cell injection
(CLL patients #3, #4 and #2). Image size: ×200 original magnification for images (bar indicates 50 µm).
(E) IHC analysis of spleen sa ples from CLL-PBMC transplanted NOG ice stained for human CD38
and Kappa and Lambda light chain at day 28 after human cell injection (CLL patient #9). Image size:
×200 original magnification for imag s (bar indic tes 50 µm).
Human CD20 staining demonstrated that the lymphoid follicle-like structures are repopulated
with human CD45+/CD20+ cells, consistent with engraftment and nodular infiltration pattern of
human CLL cells in these mice (Figure 3C + Figure S2A). CLL follicle-like structures developed with
all 24 tested CLL samples, including those with good prognosis (del 13q14, normal karyotype) and
intermediate prognosis (trisomy 12) (Figure 3D). Furthermore, we could detect lambda or kappa light
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chains dependent on the CLL phenotype (Figure 3E + Figure S2B), and found, as previously described,
differentiation of CLL cells into plasma cells in about 10% of the cells within the lymphoid follicle in
the spleens. In contrast, in BRG mice we could not detect any huCD20+ cells within the spleen or other
tissues, and found a phenotypically untouched spleen in those mice (Figure 3C).
In the NOG mouse transplantation model, CLL samples obtained from patients while receiving
chlorambucil treatment also showed robust, and only slightly decreased, engraftment compared to
their matched pretreatment control samples (Figure S3). In contrast, the transplantation of previously
frozen CLL samples (n = 12) did not result in any engraftment >1% in NOG mice, which indicates that
it is essential to use freshly isolated CLL cells for engrafting non-conditioned NOG mice.
2.4. Phenotypic Time Course of CLL Engraftment
White blood cell (WBC) counts, spleen weights and liver weights increased over the first
4 weeks (d 28), and then were stable until 8 weeks after CLL transplantation (Figure 4A,B).
Immunohistochemistry (IHC) stainings revealed that during the first 4 weeks, splenomegaly was
mainly induced by expanding CLL cells, which showed nodular CLL infiltrates reminiscent to CLL
pseudofollicles in humans. Starting d 28 after transplantation, T cells started to surround the CLL
cells (CD7 staining), and seemed to limit their further expansion, while the T cells themselves slowly
infiltrated the complete spleen (Figure 4C + Figure S1).
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Figure 4. Long-term engraftment of human CLL cells in NOG mice. (A) Mean WBC counts in the PB of
transplanted NOG mice 14, 28 and 56 days after human cell injection (CLL Patients #9–#10, n = 3 per
patient and time point). (B) Mean spleen and liver weights of CLL-PBMC transplanted NOG mice at
two, four and eight weeks after transplantation (CLL patients #9–#10, n = 3 per patient and time point).
(C) IHC stainings of spleens from CLL-PBMC transplanted NOG mice for human CD20 (right) and
CD7 (left) 14, 28 and 56 days after human cell injection (CLL Patient #9). HuCD20 shows B-CLL cells
and CD7 human T cells. Image size: x25 original magnification for upper images (bar indicates 500 µm)
and ×100 original magnification for lower images (bar indicates 200 µm).
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2.5. Effect of Autologous T Cell Quantity on CLL Cell Engraftment in NOG Mice
Next, we aimed to understand whether we could completely deplete the human donor T cells from
CLL grafts prior to transplantation without compromising engraftment efficiency. There are conflicting
reports in the literature regarding the role of autologous T cells in CLL-xenograft transplantations,
with some suggesting that they may be indispensable for engraftment [27] and others suggesting a
benefit of their total depletion [23]. Based on our own set of experiments, we compared CLL cell
engraftment in the transplantation with the highest number of co-engrafted T cells (T high, Tx2) with
the CLL cell engraftment in the transplantation with the lowest T cell co-engraftment (T low, Tx4).
Although the numbers of injected CLL-PBMCs were equal in both experiments, there was a more than
100-fold difference in engrafting T cell numbers 28 days after transplantation in the spleen, BM and
PB among those two different sets of transplantations (Figure 5A). In contrast to T cell numbers,
engrafting CLL cell numbers in the spleen were nearly equal 28 days after transplantation, regardless
of initially transferred T cell numbers and regardless of the frequency of engrafted T cells at d28. CLL
cell engraftment into the BM was better, if initial T cell co-transfers were low (Figure 5A).
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Figure 5. The role of autologous T cells on CLL cell engraftment in NOG mice. (A) Mean numbers
of human T cells and CLL cells in the spleen, femur and PB of NOG mice of transplantation T high
(CLL patient #2, n = 4) and T low (CLL patient #4, n = 3). (B) Direct comparison of relative CLL cell
engraftment in NOG mice receiving either CLL-PBMCs (n = 3, wo) or CLL-PBMCs with reduced or
depleted autologous T cell fractions (n = 3, w). Left graph shows CLL#11 and right graph CLL#13.
(C) Table depicts the amount of human T cells in CLL-PBMCs of CLL#11 and CLL#13 after T cell
reduction or T cell depletion before injection into NOG mice.
Next, we systematically compared CLL cell engraftment in spleens, BM and PB with T cell
engraftment in the same organs. Further, we compared the T cell numbers and T cell fractions within
the original graft in all performed experiments and for each mouse (Figure S3A–D). While we did
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not find any clear correlation between T cell transfer numbers and CLL cell engraftment, we found
that engrafting T cell numbers in the PB positively correlated with CLL cell engraftment in the PB
(Figure S3C). There was also a significant, albeit much lower, positive correlation between engrafting T
cells in the spleen and engrafting CLL cells in the spleen (Figure S4A), which indicates that T cells
might at least in some contexts support CLL engraftment. In order to directly compare the influence
of initial T cell co-transfers on CLL cell engraftment within the same CLL sample in our model,
we adjusted T cell numbers experimentally by performing CD3 Macs separation to either partially
reduce or deplete T cells. Partial T cell reduction from about 4.85% to 3.67% (Patient #11) and 8.87% to
3.40% (Patient #13) increased the total and relative numbers of engrafting CLL cells in all organs 28
days after transplantation 3–8 fold (Figure 5B,C). In contrast, near-total T cell depletion of 4.85% to
0.06% T cells (Patient #11) and 8.87% to 0.37% T cells (Patient #13) did not improve CLL engraftment
(Figure 5B,C). Thus, our results confirm previous experiments from other groups and indicate that
numbers of co-transferred T cells can indeed influence the engraftment of CLLs into NOG mice and
frequencies of 2%–4% T-cells are required for good engraftment, while total depletion of T cells blocks
sufficient CLL engraftment.
2.6. Model Validation Using Ibrutinib Treatment to Block CLL Expansion in Vivo
To test novel compounds for CLL patients, models are needed which closely recapitulate
key features of the human disease. Despite the development of various CLL co-culture models,
the long-term culture of primary CLL cells in vitro is challenging and only partially recapitulates
treatment responses seen in CLL patients. Therefore, CLL xenograft models in mice hold promise
in recapitulating further aspects of CLL biology, including the interplay with the microenvironment
and the additional interaction with autologous transplanted T cells known to be clinically relevant
in patients. Ibrutinib is highly effective in the treatment of CLL patients by blocking B-cell receptor
signaling and microenvironmental interactions [34–37].
Previous xenograft mouse models have demonstrated efficacy of BTK inhibitors in vivo [25,38].
To investigate if our NOG/CLL xenograft mouse model is feasible for the validation of therapeutic agents,
we treated CLL-PBMC transplanted NOG mice (n = 5 per group) with low-dose ibrutinib (25 mg/kg
body weight qd p.o.) or vehicle control for 14 days, starting one week post-transplantation. During the
course of treatment, ibrutinib caused a two-fold reduction in the number of CLL cells detected in the
spleen and PB, but only a slight effect on CLL cell numbers in the BM (Figure 6A). Concomitantly, human
B cell numbers were strongly reduced, while human T cell numbers remained unchanged, consistent
with the BTK-kinase being selectively important for the B cell receptor bearing cell compartment.
Immunohistochemistry confirmed that ibrutinib selectively and completely abrogated the observed
nodular infiltration pattern of CLL cells in the spleen, with no apparent effects on infiltrating T cells
(Figure 6D,E). These responses are remarkably similar to the clinical effects of ibrutinib in CLL patients.
Notably, CLL patients first respond to ibrutinib treatment with reduced CLL cell infiltration in the
spleen and in lymph nodes, but an increase in circulating CLL numbers in the PB due to enhanced
mobilization of the CLL cells. A reduction in the number of CLL cells in the PB and also the BM begins
to manifest itself only at later time points, up to several months after the start of ibrutinib treatment,
implicating that our mouse model indeed closely recapitulates treatment responses seen in patients.
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Figure 6. Model validation using ibrutinib treatment to block CLL infiltration in NOG mice. (A) Mean
number of CLL cells in the spleen of CLL-PBMC transplanted NOG mice (CLL patient #12) with control
vehicle treatment (n = 5) or after 14 days of ibrutinib (25 mg/kg BW) treatment (n = 5) which was
started one week post-transplantation and was administered once a day orally. (B) Mean number
of CLL cells in the femur of CLL-PBMC transplanted NOG mice (CLL patient #12) after two weeks
of ibrutinib treatment (25 mg/kg BW, n = 5). (C) Mean number of CLL cells in the PB of CLL-PBMC
transplanted NOG mice after 14 days of ibrutinib treatment (25 mg/kg BW, CLL patient #12, n = 5).
(D) NACE staining from spleen sections of CLL-PBMC transplanted control and ibrutinib treated (25
mg/kg BW, CLL patient #12, n = 5) NOG mice. Image size: x100 original magnification for images (bar
indicates 200 µM). (E) IHC staining for human CD20 in the spleen of CLL-PBMC transplanted NOG
mice after two weeks of ibrutinib treatment (25 mg/kg BW, CLL patient #12, n = 5. Image size: x25
original magnification for left images (bar indicates 500 µm), ×100 original magnification for images
in the middle (bar indicates 200 µm) and ×400 original magnification for right images (bar indicates
50 µm)).
3. Discussion
To study CLL biology and to test novel compounds for treating CLL patients, models are needed
which closely recapitulate key features of the human disease. Despite the development of various CLL
co-culture models, the long-term culture of primary CLL cells in vitro is challenging and drug treatments
only partially recapitulate treatment responses seen in CLL patients. Therefore, CLL xenograft models
in mice hold promise to recapitulate further aspects of CLL biology, including the interplay with the
microenvironment [14] and the additional interaction with autologous transplanted T cells known to
be clinically relevant in patients [39–41].
Most CLL xenograft mouse models so far use conditioning regimens like irradiation or
chemotherapy to prime the mice before CLL injection, with the consequence of destroying or at
least changing the hematopoietic stem cell niche and the microenvironment in primary and secondary
lymphoid organs [24,31]. Furthermore allograft settings were introduced to improve the CLL
engraftment by adding allogeneic CD34+ cord blood cells and antigen presenting allogeneic CD14+
monocytes or CD19+ B cells, with the consequence of unforeseeable immunological changes in CLL
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biology [27]. To circumvent such implications on the microenvironment and the immune system, we
intended to develop a CLL xenograft protocol without any conditioning regimens. Furthermore, we
aimed to focus on early stage, and good prognosis CLL samples, as they are underrepresented in the
previous studies despite their frequent occurrence [24,31].
In the initial experiments, we directly compared the engraftment efficiency of good/intermediate
prognosis, and early stage (Rai 0–II) CLL cells into un-manipulated BRG versus NOG mice.
Our xenograft studies with both mouse strains clearly demonstrated a huge advantage of the NOG
mouse strain over the BRG mouse strain. Notably, the CLL engraftment in the spleen was increased
more than 20-fold in NOG versus BRG mice. While we found a mostly nodular CLL infiltration pattern
in the spleen of NOG mice, they were not present in BRG mice. Moreover, normal human B cells and
human T cells, co-transferred with the CLL cells, showed much better engraftment in NOG versus BRG
mice. While both mouse strains are devoid of murine T-, B- and NK cells and have downregulated
cytokine receptor signaling pathways like IL2, IL4, IL7, IL9, IL15 and IL21, NOG mice show additional
alterations in macrophage functionality and the function of the innate immune system regarding
complement activation.
Besides good prognostic CLLs, we then extended our studies to CLL samples under chemotherapy
treatment and also to more aggressive late stage/poor prognosis CLLs. We found CLL engraftment in
NOG mice with all tested conditions, indicating that our CLL xenograft model is feasible for all CLL
subtypes, and is even functional for CLLs under chemotherapy. Nevertheless, the level of engraftment
strongly differed in between patients without a clear correlation towards CLL genetics or clinical
course. The most striking difference in engraftment capacity was shown in between fresh and frozen
CLL cells, with a huge advantage towards freshly isolated CLL cells.
In contrast to previous studies using the NOG mouse strain, we did not irradiate our mice, nor
did we humanize our mice with allogeneic CD34+ cord blood cells or antigen presenting cells like
allogeneic CD14+ monocytes or CD19+ B-lymphocytes. These experimental simplifications in the
protocol allow a very easy, effective and reproducible approach to establishing xenograft models for
different CLL subtypes. Beyond the simplified handling in our protocol, the resulting xenografts may,
in several regards, be more physiological compared to the other models. Firstly, the humanization of
mice with human CD34+ cord blood cells or human CD14+ monocytes sets up an “allogeneic” context
for the transplanted patient-derived CLL cells, on top of the xenogeneic context already provided
in the recipient mice. This design will surely cause immune responses like graft-versus-leukemia
effects which do not take place in CLL patients and are more reminiscent of an allogeneic BM
transplantation setting. Secondly, a number of studies have shown that irradiation of mice severely
alters the composition of niche cells within the BM and in other organs [42–44]. In the case of CLL, the
malignant cells are vitally dependent on the interaction with an appropriate microenvironment [13,14],
and niche alterations may severely alter their engraftment and expansion capacity. Our xenograft
mouse model using unmanipulated NOG mice does not require additional allogeneic human stem cell
support or the addition of allogeneic human antigen presenting cells. The reason for this might be
the lack of irradiation in our model, which implies that microenvironmental interactions, as well as
niche interactions, and also the viability and myeloid differentiation potential of murine HSCs is not
hampered, and does not have to be replaced by human cells. Furthermore, we do not need to add
allogeneic antigen presenting cells, as we find robust engraftment of autologous B cells and monocytes
in addition to the CLL cells in the NOG model, which are co-transferred upon PBMC injection (Table
S1). While these considerations speak in favor of our NOG CLL xenograft protocol, there are also
some trade-offs to be considered. Most obviously, our mouse model is associated with an uncontrolled
expansion of donor-derived human T cells after 6–8 weeks, which may hamper the analysis of CLL
biology that requires a longer follow-up period, and future studies aim to block the T cell expansion
in vivo by the use of CD3/4/8 antibodies.
Further improvements for CLL engraftment without irradiation might come from humanized
mouse models which express physiological levels of human IL-6, and allow improved B cell
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reconstitution and function [45]. Furthermore, Kit-deficient NOG mice (NBSGW = NOD,B6.SCID
IL2rγ-/- KitW41/W41) show improved huHSC engraftment with a bias towards the lymphoid lineage
and might therefore be valuable for CLL engraftment [46,47].
The role of different levels of autologous transplanted T cells co-transferred with CLL cells was
previously examined in various xenograft mouse models and conflicting conclusions have been drawn
regarding the T cell requirements for CLL engraftment. Bagnara et al. showed a direct correlation
between frequencies of autologous T cells in the PB of xenografted mice and the expansion of the
leukemic CLL cells [27]. In contrast, Dürig and Shimoni have shown that T cells inhibit CLL engraftment
at least for early stage CLL samples and T cell depletion improves the CLL engraftment [23,24]. In our
hands, near-total depletion of T cells reduces the engraftment of CLL cells, but, similar to results from
humanized mice [26], a moderate reduction of T cell co-transfer to about 2% to 4% appears to be of
advantage for CLL engraftment. Furthermore, we found that T cell numbers in the PB and spleen
positively correlated with CLL cell numbers in the same organs, which indeed implicates that T cells at
a moderate frequency support CLL growth in mice. Obviously, our analysis is not yet detailed enough
to narrow down the quantitative perspective or to allow qualitative conclusions applicable to all CLL
subtypes, but supports the previous findings from humanized mice [26].
Finally, we have established initial experimental support to validate our model in a setting of
ibrutinib treatment in CLL. Similar to what has been reported in CLL patients [34,36,37], ibrutinib
treatment effectively reduced the organ infiltration of the spleen with CLL cells within only two weeks
of treatment, and the observed nodular infiltration pattern of CLL cells completely disappeared upon
ibrutinib treatment. In contrast, there was no strong and significant response seen in the BM and PB.
This response phenotype exactly reflects the human situation, where ibrutinib treatment shrinks lymph
nodes and spleens within a very short time frame, but frequently results in increased CLL counts in
the PB during the first weeks, which slowly declines over many months.
In conclusion, we have developed a reliable and easy-to-use xenograft protocol (details shown in
Table 1) for all CLL subtypes including patient samples with good prognosis CLL without the bias
of humanization and irradiation, which can be broadly used to study CLL biology and to perform
drug treatments.
Table 1. CLL xenograft protocol.
1. Take 20–40 mL of fresh peripheral blood (PB) in EDTA tubes from CLL patients (>20.000 WBC/µL)
2. Isolate PBMCs (CLL cells, T- and B cells, monocytes) by Ficoll density centrifugation
3. Count isolated PBMCs, quantify CLL cells, T cells and B cells by flow cytometry (CD19, CD5)
Step 1–3 within 3 h
4.
(a) T cell quantity <4% proceed to step 5
(b) T cell quantity >4%: MACS-separation with CD3+ selection
5. Dilute 70 x 10 E6 CLL-PBMCs in 400 µL of HBSS
6. Inject cell suspension half i.p. and half retro-orbital into 8–11 weeks old NOG mice
7. For treatment studies: Start at day 7 post transplantation, 14–21 days of treatment
8. Final analysis:
(a) Organ weights: spleen and liver
(b) Histology: liver, 1/3 of spleen and 1 tibia
(c) Cell counts: 2/3 of spleen and 1 femur
(d) FACS: stain cells from spleen, BM and PB for human CD45, CD19 and CD5
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4. Materials and Methods
4.1. CLL Patient Samples
This study was approved by the Institutional Review Board of the University Medical Centre
Freiburg (Reference number 44/08). Peripheral blood samples were obtained with informed consent in
accordance with the Helsinki Declaration of 1975 from 24 B-CLL patients who were either untreated,
or off therapy for at least 6 months (Table S1). CLL cases were characterized for IgVH mutational status,
disease stage according to Binet and Rai criteria and history of treatment. Genetic aberrations were
analyzed by chromosomal and FISH analysis and copy number changes were verified by SNP arrays
(patient characteristics are shown in Table S1). PBMCs were separated by Ficoll gradient centrifugation
and used freshly. Some samples were frozen in fetal calf serum (FCS) with 10% dimethyl sulfoxide
(DMSO) to compare their engraftment with the fresh samples (n = 12).
4.2. Transplantation of BRG and NOG Mice
All animal experiments were approved by the Regierungspräsidium Freiburg and were performed
in accordance with the US National Institutes of Health Statement of Compliance with Standards for
Humane Care and Use of Laboratory Animals. BRG (Balb/cRag2-/-IL2rg-/- /C.Cg-Rag2tm1Fwa-/-Il2rgtm1Sug/
JicTac) and NOG (NOD/Shi-scid IL2rg-/-NOD.Cg-PrkdcscidIl2rgtm1Sug/ JicTac) mice were obtained from
Taconic, and handled under sterile conditions. Mice were transplanted at 9 to 11 weeks of age with
PBMCs from primary human CLL samples, isolated within 2 h of venipuncture by Ficoll density
centrifugation. Therefore the interlayer cells were collected, washed twice, counted and resuspended in
HBSS. A total of 70 × 106 PBMCs was suspended in 0.4 mL HBSS, and transplanted using retro-orbital
(0.2 mL) and i.p. (0.2 mL) injection. Disease development was monitored by weight measurements
twice a week, biweekly blood cell counts, and FACS staining of the PB with APC-labelled anti-human
CD45 antibody, PE-labelled anti-human CD19 antibody and V450-labeled anti-human CD5 antibody
(all BD). Two, four or eight weeks after transplantation, mice were sacrificed, and spleen as well as BM
cells were harvested and filtered unless noted otherwise. Erythrocyte lysis was followed by assessing
total cell counts, and FACS staining for human CD45, CD19, and CD5. Cells were analyzed with the
CyanADP flow cytometer (Beckman Coulter) and flow cytometric data were analyzed with the FlowJo
7.6 software (TreeStar). Engraftment was defined as > 1% human cells within spleen, bone marrow or
peripheral blood.
4.3. Histology and Immunohistochemistry (IHC)
Spleens and tibiae were fixed in 4% buffered formalin, and BM was decalcified in an EDTA
solution. After paraffin-embedding, sections were de-paraffinized in xylene and graded alcohols as
described elsewhere [48]. Hemotoxylin and Eosin (H&E) and chloracetate esterase staining followed
standard protocols. After specific antigen retrieval in “low pH target retrieval solution” (Dako) for
30 min, immunohistochemical staining was performed using antibodies against human CD45 (IR751,
clone 2B11+PD7/26), human CD20 (IR604, clone L26), and human CD7 (M7255, clone CBC.37, all from
DAKO, ready to use). The EnVision FLEX System (Dako) was used for signal visualization. Sections
were counterstained with hematoxylin (Dako) and mounted.
4.4. T Cell Reduction or Depletion
Mononuclear cells were isolated from whole blood samples of CLL patients by Ficoll gradient
separation, followed by CD3+ selection with anti-CD3 magnetic microbeads (Miltenyi Biotec) and
separation with Macs Columns and Separators (Miltenyi Biotech). Purity was determined by
flow cytometry.
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4.5. Ibrutinib Treatment
Treatment of CLL-PBMC transplanted NOG mice started one week after transplantation and
lasted for two weeks. Specifically, mice were divided into two subgroups (vehicle control and ibrutinib
at 25 mg/kg body weight), matched for CLL cell count in the PB, total blood cell counts and body
weight. Ibrutinib was obtained from Janssen-Cilag. Ibrutinib powder was dissolved in H2O with 30%
PEG300 and 1% Tween20 as well as 1% DMSO. Ibrutinib was applied according to body weight using
oral gavage. Disease development was monitored by daily body weight measurements. After 2 weeks
of treatment, mice were sacrificed, and spleen and BM cells were harvested and filtered. Erythrocyte
lysis was followed by total cell counts and FACS staining for human CD5, human CD19 and human
CD45 (BD). Harvested cells were analyzed with the CyanADP flow cytometer (Beckman Coulter) and
flow cytometric data were analyzed with the FlowJo 7.6 software (TreeStar).
4.6. Statistical Analysis
Data is represented as the mean +/− standard error of the mean (SEM). Comparisons between
parameters were performed using a two-tailed, paired or unpaired Student’s t-test (Prism5, GraphPad
Software, San Diego, CA, USA). For all analyses, p < 0.05 was considered statistically significant.
Correlations were assessed with the Pearson correlation coefficient.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/20/24/
6277/s1.
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